The Lymphedema drugs in development market research report provides comprehensive information on the therapeutics under development for Lymphedema, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Lymphedema. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Lymphedema and features dormant and discontinued products.
GlobalData tracks seven drugs in development for Lymphedema by seven companies/universities/institutes. The top development phase for Lymphedema is phase ii with four drugs in that stage. The Lymphedema pipeline has seven drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Lymphedema pipeline products market are: Herantis Pharma, AnGes and Puretech Health.
The key targets in the Lymphedema pipeline products market include Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6), Vascular Endothelial Growth Factor C (Flt4 Ligand or Vascular Endothelial Growth Factor Related Protein or VEGFC), and Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF).
The key mechanisms of action in the Lymphedema pipeline product include Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) Inhibitor with one drug in Phase II. The Lymphedema pipeline products include five routes of administration with the top ROA being Parenteral and five key molecule types in the Lymphedema pipeline products market including Gene Therapy, and Small Molecule.
Lymphedema overview
Lymphedema is an abnormal buildup of lymph fluid (protein-rich fluid) in the soft body tissues due to a damaged or blocked lymphatic system. It can be a primary lymphedema (born with lymphedema) or a secondary lymphedema (damage to the lymphatic system due any surgery, cancer, cancer treatment, infection, etc). Possible signs include swelling of the arms or legs.
For a complete picture of Lymphedema’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
